Research & Literature

Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century.

Pulte D, Jansen L, Castro FA, et al.

British journal of haematology 2015; (171(2)):189-196 doi:10.1111/bjh.13537.

Diagnostic reference range of κ/λ free light chain ratio to screen for Bence Jones proteinuria is not significantly influenced by GFR.

Schmidt-Hieltjes Y, Elshof C, Roovers L, Ruinemans-Koerts J

European journal of haematology 2016; (96(5)):527-31 doi:10.1111/ejh.12632.

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.

Palumbo A, Avet-Loiseau H, Oliva S, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015; (33(26)):2863-9 doi:10.1200/JCO.2015.61.2267.

Maintenance therapy for multiple myeloma in the era of novel agents.

Facon T

Hematology. American Society of Hematology. Education Program 2015; (2015()):279-85 doi:10.1182/asheducation-2015.1.279.

Should routine laboratories stop doing screening serum protein electrophoresis and replace it with screening immune-fixation electrophoresis? No quick fixes: Counterpoint.

Smith JD, Raines G, Schneider HG

Clinical chemistry and laboratory medicine 2016; (54(6)):967-71.

Phagocyte function decreases after high-dose treatment with melphalan and autologous stem cell transplantation in patients with multiple myeloma.

Wichert S, Pettersson Å, Hellmark T, et al.

Experimental hematology 2016; (44(5)):342-351.e5.

Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma: A Retrospective Analysis of 229 Patients.

Jian Y, Chen X, Zhou H, et al.

Medicine 2016; (95(19)):e3521 doi:10.1097/MD.0000000000003521.

Updated Diagnostic Criteria and Staging System for Multiple Myeloma.

Rajkumar SV

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2016; (35()):e418-23 doi:10.14694/EDBK_159009.

Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study.

Garderet L, Beohou E, Caillot D, et al.

Haematologica 2016; (101(11)):1390-1397 doi:10.3324/haematol.2016.150334.

MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.

Mateos MV, Landgren O

Cancer treatment and research 2016; (169()):3-12 doi:10.1007/978-3-319-40320-5_1.

Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma.

Kastritis E, Terpos E, Roussou M, et al.

Haematologica 2017; (102(3)):593-599 doi:10.3324/haematol.2016.145078.

Diagnostics for multiple myeloma.

Yamazaki E

[Rinsho ketsueki] The Japanese journal of clinical hematology 2016; (57(10)):2096-2103 doi:10.11406/rinketsu.57.2096.

Recommend upfront consolidation with high-dose melphalan and autologous stem cell support.

Shah GL, Giralt SA

Seminars in oncology 2016; (43(6)):707-708 doi:10.1053/j.seminoncol.2016.11.007.

Clinical profile of kidney involvement preceding diagnosis of multiple myeloma; a single center experience.

Balwani MR, Gumber MR, Shah PR, et al.

Journal of nephropharmacology 2016; (5(2)):98-101.

Rare Pedal Manifestation of Diffuse Multiple Myeloma Lesions.

Saviet BM, Marcoux JT, Narayanasami U

The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons 2017; (56(2)):357-361 doi:10.1053/j.jfas.2016.11.020.

Multiple Myeloma: Diagnosis and Treatment.

Michels TC, Petersen KE

American family physician 2017; (95(6)):373-383.

Lenalidomide-induced eosinophilic pneumonia.

Toma A, Rapoport AP, Burke A, Sachdeva A

Respirology case reports 2017; (5(4)):e00233 doi:10.1002/rcr2.233.

Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests.

Heaney JLJ, Campbell JP, Griffin AE, et al.

British journal of haematology 2017; (178(2)):220-230 doi:10.1111/bjh.14753.

Comparison of bone marrow aspiration cytology with bone marrow trephine biopsy histopathology: An observational study.

Gilotra M, Gupta M, Singh S, Sen R

Journal of laboratory physicians 2017; (9(3)):182-189 doi:10.4103/JLP.JLP_117_16.

Evaluation of a new free light chain ELISA assay: bringing coherence with electrophoretic methods.

Jacobs JFM, de Kat Angelino CM, Brouwers HMLM, et al.

Clinical chemistry and laboratory medicine 2018; (56(2)):312-322 doi:10.1515/cclm-2017-0339.

Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.

Syed YY

Drugs 2017; (77(13)):1473-1480 doi:10.1007/s40265-017-0795-0.

Multiple Myeloma Presenting as Acute Renal Failure in the Absence of Other Characteristic Features.

Gastelum ZN, Biggs DM, Scott A

Cureus 2017; (9(9)):e1703 doi:10.7759/cureus.1703.

Light chain multiple myeloma: an evaluation of its biochemical investigations.

Zahari Sham SY, C Thambiah S, Samsudin IN, Lim SM

The Malaysian journal of pathology 2017; (39(3)):311-315.

Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.

Dhakal B, Szabo A, Chhabra S, et al.

JAMA oncology 2018; (4(3)):343-350 doi:10.1001/jamaoncol.2017.4600.

Management of Multiple Myeloma.

Kumar SK

Journal of the National Comprehensive Cancer Network : JNCCN 2018; (16(5S)):624-627 doi:10.6004/jnccn.2018.0040.

Lower glomerular filtration rate predicts increased hepatic and mucosal toxicity in myeloma patients treated with high-dose melphalan.

Tamaki M, Nakasone H, Gomyo A, et al.

International journal of hematology 2018; (108(4)):423-431 doi:10.1007/s12185-018-2507-2.

Nucleic acid based risk assessment and staging for clinical practice in multiple myeloma.

Gupta R, Kaur G, Kumar L, et al.

Annals of hematology 2018; (97(12)):2447-2454 doi:10.1007/s00277-018-3457-8.

Bone Marrow Disease Profile in Geriatric Patients: An Institutional Experience.

Gulati A, Mandal T, Kaushal V, et al.

Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 2018; (34(3)):540-543 doi:10.1007/s12288-017-0871-3.

Prognostic impact of hyperdiploidy in multiple myeloma patients with high-risk cytogenetics: a pilot study in China.

Mei J, Zhai Y, Li H, et al.

Journal of cancer research and clinical oncology 2018; (144(11)):2263-2273 doi:10.1007/s00432-018-2732-3.

Biological determinants of health disparities in multiple myeloma.

Smith CJ, Ambs S, Landgren O

Blood cancer journal 2018; (8(9)):85 doi:10.1038/s41408-018-0118-z.

[Diagnosis and treatment of kidney involvement in plasma cell diseases : Renal involvement in multiple myeloma and monoclonal gammopathies].

Gödecke V, Schmidt JJ, Bräsen JH, et al.

Der Internist 2019; (60(1)):10-22 doi:10.1007/s00108-018-0538-7.

New Drugs in Multiple Myeloma.

Kunacheewa C, Orlowski RZ

Annual review of medicine 2019; (70()):521-547 doi:10.1146/annurev-med-112017-091045.

High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma.

Thakurta A, Ortiz M, Blecua P, et al.

Blood 2019; (133(11)):1217-1221 doi:10.1182/blood-2018-10-880831.

B-cell maturation antigen directed monoclonal antibody therapies for multiple myeloma.

Eckhert E, Hewitt R, Liedtke M

Immunotherapy 2019; (11(9)):801-811 doi:10.2217/imt-2018-0199.

[Bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplantation and maintenance in 200 patients with multiple myeloma: long-term follow-up results from single center].

Wu Q, Liu JR, Huang BH, et al.

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2019; (40(6)):453-459 doi:10.3760/cma.j.issn.0253-2727.2019.06.002.

Role of bone-modifying agents in advanced cancer.

Desautels DN, Harlos CH, Jerzak KJ

Annals of palliative medicine 2020; (9(3)):1314-1323 doi:10.21037/apm.2019.08.07.

High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group.

Hus I, Mańko J, Jawniak D, et al.

Oncology letters 2019; (18(6)):5811-5820 doi:10.3892/ol.2019.10929.

Multiple myeloma: 2020 update on diagnosis, risk-stratification and management.

Rajkumar SV

American journal of hematology 2020; (95(5)):548-567 doi:10.1002/ajh.25791.

Recent Advances in the Management of Smoldering Multiple Myeloma.

Madhira BR, Konala VM, Adapa S, et al.

World journal of oncology 2020; (11(2)):45-54 doi:10.14740/wjon1245.

Historical perspectives in clinical pathology: Bence Jones protein-early urine chemistry and the impact on modern day diagnostics.

Sewpersad S, Pillay TS

Journal of clinical pathology 2021; (74(4)):212-215 doi:10.1136/jclinpath-2020-206675.

African American Patients With Multiple Myeloma: Optimizing Care to Decrease Racial Disparities.

Pierre A, Williams TH

Clinical journal of oncology nursing 2020; (24(4)):439-443 doi:10.1188/20.CJON.439-443.

Pulmonary arterial hypertension in a patient with multiple myeloma during carfilzomib treatment: in search of better management.

Rago A, Siniscalchi A, Tordi A, et al.

Tumori 2021; (107(6)):NP37-NP40 doi:10.1177/0300891621990427.

Autologous stem cell transplantation in elderly multiple myeloma patients aged ≥65 years: a two-centre Australian experience.

Er J, Routledge D, Hempton J, et al.

Internal medicine journal 2021; (51(2)):280-283 doi:10.1111/imj.15182.

A Case Report of Acquired Factor X Deficiency in a Patient With Multiple Myeloma.

Sabobeh T, Brugioni EK, Masoud A, et al.

Cureus 2021; (13(2)):e13293 doi:10.7759/cureus.13293.

Involved free light chain: an early independent predictor of response and progression in multiple myeloma.

Gran C, Afram G, Liwing J, et al.

Leukemia & lymphoma 2021; (62(9)):2227-2234 doi:10.1080/10428194.2021.1907370.

Evolution of Treatment Paradigms in Newly Diagnosed Multiple Myeloma.

Elnair RA, Holstein SA

Drugs 2021; (81(7)):825-840 doi:10.1007/s40265-021-01514-0.

Current Approach to Managing Patients with Newly Diagnosed High-Risk Multiple Myeloma.

Marneni N, Chakraborty R

Current hematologic malignancy reports 2021; (16(2)):148-161 doi:10.1007/s11899-021-00631-7.

Dental pathologies in tumor patients with bone metastases or multiple myeloma scheduled for antiresorptive therapy.

Laimer J, Hechenberger M, Müller D, et al.

Future oncology (London, England) 2021; (17(21)):2705-2711 doi:10.2217/fon-2020-1240.

Bone marrow aspiration and biopsy: techniques and practice implications.

Tomasian A, Jennings JW

Skeletal radiology 2022; (51(1)):81-88 doi:10.1007/s00256-021-03882-w.

A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics.

Awada H, Thapa B, Awada H, et al.

Cells 2021; (10(8)) doi:10.3390/cells10081961.

Pathogenesis and treatment of multiple myeloma bone disease.

Hiasa M, Harada T, Tanaka E, Abe M

The Japanese dental science review 2021; (57()):164-173 doi:10.1016/j.jdsr.2021.08.006.

Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial.

Klein EM, Tichy D, Salwender HJ, et al.

Cancers 2021; (13(19)) doi:10.3390/cancers13194856.

Cutaneous Multiple Myeloma.

Miriyala LKV, Avasthi D

Cureus 2021; (13(9)):e17779 doi:10.7759/cureus.17779.

Mortality trends in multiple myeloma after the introduction of novel therapies in the United States.

Binder M, Nandakumar B, Rajkumar SV, et al.

Leukemia 2022; (36(3)):801-808 doi:10.1038/s41375-021-01453-5.

[Skeletal changes in plasma cell dyscrasias].

Weber TF, Mokry T

Der Radiologe 2021; (61(12)):1078-1089 doi:10.1007/s00117-021-00932-1.

[Application of Conditioning Regimen with Busulfan and Cyclophosphamide in Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma].

Xu Y, Zhou J, Ma L, et al.

Zhongguo shi yan xue ye xue za zhi 2021; (29(6)):1831-1836 doi:10.19746/j.cnki.issn.1009-2137.2021.06.024.

A prospective study of Skeletal survey versus Low-dose whole-body CT for Osteolytic lesions in Multiple Myeloma.

Gundesen MT, Asmussen JT, Haukås E, et al.

European journal of haematology 2022; (108(5)):423-429 doi:10.1111/ejh.13749.

Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group.

Raje NS, Anaissie E, Kumar SK, et al.

The Lancet. Haematology 2022; (9(2)):e143-e161 doi:10.1016/S2352-3026(21)00283-0.

Incidence and Prognostic Significance of High-Risk Cytogenetically Abnormalities in Multiple Myeloma Patients in Colombia.

Combariza JF, Ordúz R, Agudelo C, et al.

Clinical lymphoma, myeloma & leukemia 2022; (22(8)):601-607 doi:10.1016/j.clml.2022.02.006.

Efficacy of Intermittent, Oral Famciclovir Prophylaxis for Bortezomib-Induced Herpes Zoster in Multiple Myeloma Patients.

Zheng G, Guan F, Han X, et al.

Frontiers in oncology 2022; (12()):843032 doi:10.3389/fonc.2022.843032.

Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.

Rajkumar SV

American journal of hematology 2022; (97(8)):1086-1107 doi:10.1002/ajh.26590.

Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.

D'Agostino M, Cairns DA, Lahuerta JJ, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(29)):3406-3418 doi:10.1200/JCO.21.02614.

Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy.

Ebraheem M, Kumar SK, Dispenzieri A, et al.

Transplantation and cellular therapy 2022; (28(11)):760.e1-760.e5 doi:10.1016/j.jtct.2022.07.030.

Bone Disease in Multiple Myeloma: Biologic and Clinical Implications.

Bernstein ZS, Kim EB, Raje N

Cells 2022; (11(15)) doi:10.3390/cells11152308.

Multiple myeloma with t(11;14): unique biology and evolving landscape.

Bal S, Kumar SK, Fonseca R, et al.

American journal of cancer research 2022; (12(7)):2950-2965.

The role of Vertebral Augmentation Procedures in the management of vertebral compression fractures secondary to multiple myeloma.

Eseonu KC, Panchmatia JR, Streetly MJ, et al.

Hematological oncology 2023; (41(3)):323-334 doi:10.1002/hon.3102.

Hyperammonemic Encephalopathy in Multiple Myeloma: A Case Report.

Vahora I, Panneerselvam E, Deoker A

Cureus 2023; (15(1)):e33626 doi:10.7759/cureus.33626.

18F-FDG PET/CT in monoclonal plasma cell disorders.

Paschali A

Hellenic journal of nuclear medicine 2023; (26 Suppl()):38-41.

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.

Voorhees PM, Sborov DW, Laubach J, et al.

The Lancet. Haematology 2023; (10(10)):e825-e837 doi:10.1016/S2352-3026(23)00217-X.

Serum-free light chain test utilisation at a South African academic laboratory and comparison with serum protein electrophoresis results.

Banderker RB, Fazel FB, Zemlin AE, et al.

African journal of laboratory medicine 2023; (12(1)):2201 doi:10.4102/ajlm.v12i1.2201.

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Sonneveld P, Dimopoulos MA, Boccadoro M, et al.

The New England journal of medicine 2024; (390(4)):301-313 doi:10.1056/NEJMoa2312054.

Smoldering Multiple Myeloma: Observation Versus Control Versus Cure.

Rajkumar SV, Bergsagel PL, Kumar S

Hematology/oncology clinics of North America 2024; (38(2)):293-303 doi:10.1016/j.hoc.2023.12.001.

Multiple myeloma initially manifesting as a solitary deep ulcer on the tongue: a case study and literature review.

Zhang Y, Wu Y, Yao L, et al.

European journal of dermatology : EJD 2023; (33(6)):618-623 doi:10.1684/ejd.2023.4628.

Plasma cell myeloma in a 9-year-old male: Case report and literature review.

Ronald K, Jacinta A, Umaru S

Clinical case reports 2024; (12(4)):e8801 doi:10.1002/ccr3.8801.

The Evolving Role of Checkpoint Inhibitors in Multiple Myeloma.

Chakrabarti R, Siegel D, Biran N

Clinical lymphoma, myeloma & leukemia 2025; (25(2)):96-108 doi:10.1016/j.clml.2024.08.004.

Clinical updates of B‑cell maturation antigen‑targeted therapy in multiple myeloma (MM) and relapsed/refractory MM (Review).

Xing R, Wang M, Wang L, et al.

International journal of molecular medicine 2025; (55(2)).

Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment.

Navab R, Futela P, Kumari V, et al.

Iranian journal of medical sciences 2025; (50(1)):1-10 doi:10.30476/ijms.2024.101739.3446.

Ciltacabtagene Autoleucel for the Treatment of Relapsed/Refractory Multiple Myeloma: Efficacy, Safety, and Place in Therapy.

Goel U, Zanwar S, Cowan AJ, et al.

Cancer management and research 2025; (17()):357-372 doi:10.2147/CMAR.S510408.

Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma.

Talarico M, Barbato S, Cattabriga A, et al.

Journal of bone oncology 2025; (51()):100669 doi:10.1016/j.jbo.2025.100669.

The Progress of Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Myeloma (Review).

Wang YN, Zhang CW, Gao YX, Ge XL

Technology in cancer research & treatment 2025; (24()):15330338251321349 doi:10.1177/15330338251321349.

Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes.

Bolarinwa A, Nagaraj M, Zanwar S, et al.

Blood cancer journal 2025; (15(1)):57 doi:10.1038/s41408-025-01264-2.

New therapies in multiple myeloma: benefits and limitations.

Jurczyszyn A, Bator M, Vesole DH, et al.

Polish archives of internal medicine 2025; (135(4)) doi:10.20452/pamw.16994.

Analysis of Ubiquitin-Conjugating Enzyme E2T (UBE2T) Protein Levels in the Bone Marrow Biopsy Specimens of Patients With Multiple Myeloma.

Wang F, Yu N, Xia R

Cureus 2025; (17(4)):e82571 doi:10.7759/cureus.82571.

[Expert consensus on the comprehensive management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma in China (2025)].

,

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2025; (46(3)):198-208 doi:10.3760/cma.j.cn121090-20241122-00469.

Eliminating the need for sequential confirmation of response in multiple myeloma.

Claveau JS, Kapoor P, Binder M, et al.

Blood 2025; (146(7)):802-805 doi:10.1182/blood.2024027949.

The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.

Ntanasis-Stathopoulos I, Filippatos C, Malandrakis P, et al.

Leukemia 2025; (39(9)):2226-2236 doi:10.1038/s41375-025-02677-5.

Efficacy and safety of etoposide + cytarabine + pegfilgrastim mobilization regimen versus G-CSF mobilization regimen alone for hematopoietic stem cell mobilization in patients with multiple myeloma and lymphoma.

Xu S, Cheng Y, Pei R, et al.

Cytotherapy 2025; (27(8)):973-979 doi:10.1016/j.jcyt.2025.05.012.

From Trials to Practice: A 2025 Review of Idecabtagene Vicleucel and Ciltacabtagene Autoleucel Efficacy Across Clinical Studies and Real-World Evidence.

Pleitez HG, Saowapa S, Maldonado AO, et al.

European journal of haematology 2025; (115(6)):533-546 doi:10.1111/ejh.70025.

Monoclonal Gammopathy Presenting with Pseudo Biclonal Pattern in Serum Protein Electrophoresis - An Interesting Perspective of Case Series.

Nethaji K, Elango K, Selvarajan S, Krishnamurthy S

EJIFCC 2025; (36(3)):387-393.